64cu-psma i&t
PeptideexperimentalImaging agent
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05653856)
Timeline
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIINHIBITOR
FOLH1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06235099 | Phase 3 | Apr 1, 2024 | Curium Pharma |
| NCT06235151 | Phase 3 | Apr 1, 2024 | Curium Pharma |
| NCT05653856 | Phase 2 | Dec 31, 2022 | Curium Pharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Curium Pharma | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1